Bradley Merrill Thompson Quoted in “Special Report: Obama Policy Wind-Up Could Affect Drugmakers, Device Companies”

Bloomberg BNA Health Care Daily Report

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA Health Care Daily Report, in “Special Report: Obama Policy Wind-Up Could Affect Drugmakers, Device Companies,” by Bronwyn Mixter, Michael D. Williamson, John T. Aquino, and Jeannie Baumann. (Read the full version – subscription required.)

Following is an excerpt:

The FDA announced its intention to draft a guidance on CDS in 2011, and held a public hearing on the topic in September 2011, attorney Bradley Merrill Thompson told Bloomberg BNA Aug. 25. Thompson, counsel for the Clinical Decision Support Coalition, is also an attorney at Epstein Becker & Green PC in Washington.

“My understanding is that it was hung up for a while when Congress was considering legislation” on CDS, Thompson said. He told Bloomberg BNA the FDA is struggling a bit with how to write it, “but I would not be surprised if it issued this fall.”